Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > REGULATORY
REGULATORY
- MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
August 26, 2024
- Astellas Pharma Employee Indicted in China
August 23, 2024
- New LDP Study Group Seeks Budget to Bolster Immunoglobulin Production
August 23, 2024
- BMS’ ROS1 Inhibitor, Janssen’s Bispecific Up for Review on Aug. 30
August 20, 2024
- Kobayashi Declares Bid for LDP Race, Urges More Investment in Pharma
August 20, 2024
- MHLW to Present Detailed Criteria for Exclusion from “Specified Clinical Trials”
August 20, 2024
- Certain Jabs to Be Exempted from Regenerative Medicine Safety Act to Facilitate Travel Vaccination
August 20, 2024
- Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
- Eisai’s ALS Therapy, Amgen’s TED Drug Up for Review on Aug. 26
August 19, 2024
- August Generic Approval List Includes AGs for at Least 3 APIs, Acofide and More
August 19, 2024
- Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
- MHLW Announces Simplified New Process for Drug Delisting
August 19, 2024
- JGA Shares Scheme of Supply Managers Council, MHLW Conferring with FTC on Feasibility
August 9, 2024
- Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
August 9, 2024
- Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
August 8, 2024
- Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
August 8, 2024
- Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
- Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
August 8, 2024
- AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
August 8, 2024
- MHLW to Issue Guidance for Setting Acceptable Limit for Nitrosamines This Fall
August 6, 2024
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…